Published in Thyroid on November 01, 2002
Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer (2013) 4.46
Molecular aspects of thyroid hormone actions. Endocr Rev (2010) 3.29
Synthesis and biological evaluation of [(18)F]tetrafluoroborate: a PET imaging agent for thyroid disease and reporter gene imaging of the sodium/iodide symporter. Eur J Nucl Med Mol Imaging (2010) 1.71
Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor. Proc Natl Acad Sci U S A (2006) 1.62
Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. Endocrinol Metab Clin North Am (2008) 1.41
The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. Mol Cell Endocrinol (2009) 1.40
Aberrant accumulation of PTTG1 induced by a mutated thyroid hormone beta receptor inhibits mitotic progression. J Clin Invest (2006) 1.37
The syndromes of reduced sensitivity to thyroid hormone. Biochim Biophys Acta (2012) 1.35
PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer. Oncogene (2008) 1.31
Impaired adipogenesis caused by a mutated thyroid hormone alpha1 receptor. Mol Cell Biol (2007) 1.23
Thyrocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors. Oncotarget (2011) 1.19
Regulation of beta-catenin by a novel nongenomic action of thyroid hormone beta receptor. Mol Cell Biol (2008) 1.15
Growth activation alone is not sufficient to cause metastatic thyroid cancer in a mouse model of follicular thyroid carcinoma. Endocrinology (2010) 1.11
Cross-talk between PI3K and estrogen in the mouse thyroid predisposes to the development of follicular carcinomas with a higher incidence in females. Oncogene (2010) 1.11
Thyroid hormone receptor beta (THRB) is a major target gene for microRNAs deregulated in papillary thyroid carcinoma (PTC). J Clin Endocrinol Metab (2010) 1.10
The thyroid hormone receptor is a suppressor of ras-mediated transcription, proliferation, and transformation. Mol Cell Biol (2004) 1.06
MiR-224 targets the 3'UTR of type 1 5'-iodothyronine deiodinase possibly contributing to tissue hypothyroidism in renal cancer. PLoS One (2011) 1.02
A case of resistance to thyroid hormone with thyroid cancer. J Korean Med Sci (2010) 1.01
Resistance to thyroid hormone is modulated in vivo by the nuclear receptor corepressor (NCOR1). Proc Natl Acad Sci U S A (2011) 1.00
Paired box gene 8-peroxisome proliferator-activated receptor-gamma fusion protein and loss of phosphatase and tensin homolog synergistically cause thyroid hyperplasia in transgenic mice. Endocrinology (2009) 1.00
Nuclear receptor corepressor is a novel regulator of phosphatidylinositol 3-kinase signaling. Mol Cell Biol (2007) 0.99
Thyroid hormone receptors and cancer. Biochim Biophys Acta (2012) 0.99
Inhibition of mTORC1 signaling reduces tumor growth but does not prevent cancer progression in a mouse model of thyroid cancer. Carcinogenesis (2010) 0.96
Thyroid hormone receptor beta mutants: Dominant negative regulators of peroxisome proliferator-activated receptor gamma action. Proc Natl Acad Sci U S A (2005) 0.96
Novel non-genomic signaling of thyroid hormone receptors in thyroid carcinogenesis. Mol Cell Endocrinol (2009) 0.96
Hypothyroidism enhances tumor invasiveness and metastasis development. PLoS One (2009) 0.96
Management of differentiated thyroid cancer in the presence of resistance to thyroid hormone and TSH-secreting adenomas: a report of four cases and review of the literature. J Clin Endocrinol Metab (2013) 0.96
Synergistic signaling of KRAS and thyroid hormone receptor β mutants promotes undifferentiated thyroid cancer through MYC up-regulation. Neoplasia (2014) 0.96
Nongenomic activation of phosphatidylinositol 3-kinase signaling by thyroid hormone receptors. Steroids (2008) 0.95
Thyroid hormone receptors are tumor suppressors in a mouse model of metastatic follicular thyroid carcinoma. Oncogene (2010) 0.94
Diet-induced obesity increases tumor growth and promotes anaplastic change in thyroid cancer in a mouse model. Endocrinology (2013) 0.92
Akt1 deficiency delays tumor progression, vascular invasion, and distant metastasis in a murine model of thyroid cancer. Oncogene (2011) 0.92
Role of TSH in the spontaneous development of asymmetrical thyroid carcinoma in mice with a targeted mutation in a single allele of the thyroid hormone-β receptor. Endocrinology (2012) 0.92
Hyperactivity, impaired learning on a vigilance task, and a differential response to methylphenidate in the TRbetaPV knock-in mouse. Psychopharmacology (Berl) (2005) 0.91
Lessons from mouse models of thyroid cancer. Thyroid (2009) 0.90
Testosterone regulates thyroid cancer progression by modifying tumor suppressor genes and tumor immunity. Carcinogenesis (2015) 0.90
Mutation of thyroid hormone receptor-β in mice predisposes to the development of mammary tumors. Oncogene (2011) 0.88
Thyroid hormone receptors regulate adipogenesis and carcinogenesis via crosstalk signaling with peroxisome proliferator-activated receptors. J Mol Endocrinol (2009) 0.87
Novel oncogenic actions of TRbeta mutants in tumorigenesis. IUBMB Life (2009) 0.86
The Role of the PAX8/PPARgamma Fusion Oncogene in Thyroid Cancer. PPAR Res (2008) 0.86
Novel functions of thyroid hormone receptor mutants: beyond nucleus-initiated transcription. Steroids (2006) 0.86
Thyroid hormone receptor mutations in cancer and resistance to thyroid hormone: perspective and prognosis. J Thyroid Res (2011) 0.85
Genetics and epigenetics of sporadic thyroid cancer. Mol Cell Endocrinol (2013) 0.85
Inhibition of tumorigenesis by the thyroid hormone receptor β in xenograft models. Thyroid (2013) 0.82
Obatoclax overcomes resistance to cell death in aggressive thyroid carcinomas by countering Bcl2a1 and Mcl1 overexpression. Endocr Relat Cancer (2014) 0.82
Approach to the patient with resistance to thyroid hormone and pregnancy. J Clin Endocrinol Metab (2010) 0.81
Activation of tumor cell proliferation by thyroid hormone in a mouse model of follicular thyroid carcinoma. Oncogene (2011) 0.81
Extranuclear signaling of mutated thyroid hormone receptors in promoting metastatic spread in thyroid carcinogenesis. Steroids (2011) 0.81
Complex temporal changes in TGFβ oncogenic signaling drive thyroid carcinogenesis in a mouse model. Carcinogenesis (2013) 0.81
Thyroid hormone receptor β suppresses SV40-mediated tumorigenesis via novel nongenomic actions. Am J Cancer Res (2012) 0.80
Oncogenic mutations of thyroid hormone receptor β. Oncotarget (2015) 0.80
Bromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model. Clin Cancer Res (2016) 0.79
Perioperative management of a patient with thyroid hormone resistance who underwent total thyroidectomy for thyroid cancer. J Anesth (2012) 0.79
The cytoplasmic domain of proEGF negatively regulates motility and elastinolytic activity in thyroid carcinoma cells. Neoplasia (2008) 0.79
Activation of the RhoB signaling pathway by thyroid hormone receptor β in thyroid cancer cells. PLoS One (2014) 0.79
Characterization of thyroid cancer in mouse models using high-frequency quantitative ultrasound techniques. Ultrasound Med Biol (2013) 0.78
Anaplastic Thyroid Carcinoma: Current Treatments and Potential New Therapeutic Options with Emphasis on TfR1/CD71. Int J Endocrinol (2014) 0.78
Three-dimensional telomere dynamics in follicular thyroid cancer. Thyroid (2013) 0.78
Metformin blocks progression of obesity-activated thyroid cancer in a mouse model. Oncotarget (2016) 0.77
Modeling anaplastic thyroid carcinoma in the mouse. Horm Cancer (2014) 0.77
Modulation of sodium iodide symporter in thyroid cancer. Horm Cancer (2014) 0.77
Oncogenic Actions of the Nuclear Receptor Corepressor (NCOR1) in a Mouse Model of Thyroid Cancer. PLoS One (2013) 0.77
Apigenin in combination with Akt inhibition significantly enhances thyrotropin-stimulated radioiodide accumulation in thyroid cells. Thyroid (2014) 0.77
Obatoclax kills anaplastic thyroid cancer cells by inducing lysosome neutralization and necrosis. Oncotarget (2016) 0.77
Modeling thyroid cancer in the mouse. Horm Metab Res (2009) 0.77
Activation of phosphatidylinositol 3-kinase signaling promotes aberrant pituitary growth in a mouse model of thyroid-stimulating hormone-secreting pituitary tumors. Endocrinology (2008) 0.77
Multiple Hürthle cell adenomas in a patient with thyroid hormone resistance. Endocrinol Diabetes Metab Case Rep (2013) 0.77
Activation of integrin-ERBB2 signaling in undifferentiated thyroid cancer. Am J Cancer Res (2014) 0.76
Mouse models of follicular and papillary thyroid cancer progression. Front Endocrinol (Lausanne) (2012) 0.76
Modeling follicular thyroid cancer for future therapies. Am J Cancer Res (2012) 0.76
Expression of stanniocalcin 1 in thyroid side population cells and thyroid cancer cells. Thyroid (2015) 0.76
SAHA-induced loss of tumor suppressor Pten gene promotes thyroid carcinogenesis in a mouse model. Endocr Relat Cancer (2016) 0.75
Thyroid hormone suppresses expression of stathmin and associated tumor growth in hepatocellular carcinoma. Sci Rep (2016) 0.75
Mutation analysis underlying the downregulation of the thyroid hormone receptor β1 gene in the Chinese breast cancer population. Onco Targets Ther (2015) 0.75
Thyroid Hormone Receptor-β (TRβ) Mediates Runt-Related Transcription Factor 2 (Runx2) Expression in Thyroid Cancer Cells: A Novel Signaling Pathway in Thyroid Cancer. Endocrinology (2016) 0.75
KRAS(G12D)-mediated oncogenic transformation of thyroid follicular cells requires long-term TSH stimulation and is regulated by SPRY1. Lab Invest (2015) 0.75
Mouse models of thyroid cancer: A 2015 update. Mol Cell Endocrinol (2015) 0.75
Coexistence of resistance to thyroid hormone and papillary thyroid carcinoma. Endocrinol Diabetes Metab Case Rep (2016) 0.75
BRAF(V600E) mutation contributes papillary thyroid carcinoma and Hashimoto thyroiditis with resistance to thyroid hormone: A case report and literature review. Oncol Lett (2017) 0.75
Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res (2007) 3.30
Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J Clin Invest (2007) 3.01
Increased cellular free cholesterol in macrophage-specific Abca1 knock-out mice enhances pro-inflammatory response of macrophages. J Biol Chem (2008) 2.87
Apoptosis regulators Bim and Fas function concurrently to control autoimmunity and CD8+ T cell contraction. Immunity (2008) 2.26
Mesothelin expression in human lung cancer. Clin Cancer Res (2007) 2.10
Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med (2010) 1.94
Improved detection of apoptotic cells in archival paraffin sections: immunohistochemistry using antibodies to cleaved caspase 3. J Histochem Cytochem (2002) 1.92
Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol (2005) 1.84
Rapid nongenomic actions of thyroid hormone. Proc Natl Acad Sci U S A (2006) 1.79
Transferable anticancer innate immunity in spontaneous regression/complete resistance mice. Proc Natl Acad Sci U S A (2006) 1.77
ACAT2 is localized to hepatocytes and is the major cholesterol-esterifying enzyme in human liver. Circulation (2004) 1.76
Cholesterol-regulated translocation of NPC1L1 to the cell surface facilitates free cholesterol uptake. J Biol Chem (2005) 1.75
Synthesis and biological evaluation of [(18)F]tetrafluoroborate: a PET imaging agent for thyroid disease and reporter gene imaging of the sodium/iodide symporter. Eur J Nucl Med Mol Imaging (2010) 1.71
Diphtheria toxin-murine granulocyte-macrophage colony-stimulating factor-induced hepatotoxicity is mediated by Kupffer cells. Mol Cancer Ther (2004) 1.68
An unliganded thyroid hormone beta receptor activates the cyclin D1/cyclin-dependent kinase/retinoblastoma/E2F pathway and induces pituitary tumorigenesis. Mol Cell Biol (2005) 1.67
AKT activation promotes metastasis in a mouse model of follicular thyroid carcinoma. Endocrinology (2005) 1.56
SMRT repression of nuclear receptors controls the adipogenic set point and metabolic homeostasis. Proc Natl Acad Sci U S A (2008) 1.46
Type 1 iodothyronine deiodinase is a sensitive marker of peripheral thyroid status in the mouse. Endocrinology (2004) 1.38
Aberrant accumulation of PTTG1 induced by a mutated thyroid hormone beta receptor inhibits mitotic progression. J Clin Invest (2006) 1.37
Pancreatic cancer cells express 25-hydroxyvitamin D-1 alpha-hydroxylase and their proliferation is inhibited by the prohormone 25-hydroxyvitamin D3. Carcinogenesis (2004) 1.37
Anthrax toxin-induced shock in rats is associated with pulmonary edema and hemorrhage. Microb Pathog (2007) 1.36
Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer. Carcinogenesis (2007) 1.35
Topology of NGEP, a prostate-specific cell:cell junction protein widely expressed in many cancers of different grade level. Cancer Res (2008) 1.34
Alterations in genomic profiles during tumor progression in a mouse model of follicular thyroid carcinoma. Carcinogenesis (2003) 1.33
Thyroid hormone stimulates hepatic lipid catabolism via activation of autophagy. J Clin Invest (2012) 1.29
Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis. Genome Biol (2013) 1.26
Spontaneous regression of advanced cancer: identification of a unique genetically determined, age-dependent trait in mice. Proc Natl Acad Sci U S A (2003) 1.25
Impaired adipogenesis caused by a mutated thyroid hormone alpha1 receptor. Mol Cell Biol (2007) 1.23
Cyclin D1 Is a Ligand-independent Co-repressor for Thyroid Hormone Receptors. J Biol Chem (2002) 1.23
Functionally impaired TR mutants are present in thyroid papillary cancer. J Clin Endocrinol Metab (2002) 1.23
Branched-chain amino acid catabolism: unique segregation of pathway enzymes in organ systems and peripheral nerves. Am J Physiol Endocrinol Metab (2003) 1.21
Loss of expression of tropomyosin-1, a novel class II tumor suppressor that induces anoikis, in primary breast tumors. Oncogene (2003) 1.20
Differential expression of thyroid hormone receptor isoforms dictates the dominant negative activity of mutant Beta receptor. Mol Endocrinol (2002) 1.17
Mutually exclusive inactivation of DMP1 and ARF/p53 in lung cancer. Cancer Cell (2007) 1.17
Regulation of beta-catenin by a novel nongenomic action of thyroid hormone beta receptor. Mol Cell Biol (2008) 1.15
Mutant thyroid hormone receptor beta represses the expression and transcriptional activity of peroxisome proliferator-activated receptor gamma during thyroid carcinogenesis. Cancer Res (2003) 1.13
Interstitial diphtheria toxin-epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice. Clin Cancer Res (2005) 1.11
Growth activation alone is not sufficient to cause metastatic thyroid cancer in a mouse model of follicular thyroid carcinoma. Endocrinology (2010) 1.11
Inhibition of acyl-coenzyme A:cholesterol acyltransferase 2 (ACAT2) prevents dietary cholesterol-associated steatosis by enhancing hepatic triglyceride mobilization. J Biol Chem (2010) 1.11
A diphtheria toxin-epidermal growth factor fusion protein is cytotoxic to human glioblastoma multiforme cells. Cancer Res (2003) 1.09
NGEP, a prostate-specific plasma membrane protein that promotes the association of LNCaP cells. Cancer Res (2007) 1.08
Effector mechanisms of the anti-cancer immune responses of macrophages in SR/CR mice. Cancer Immun (2006) 1.02
A human bone morphogenetic protein antagonist is down-regulated in renal cancer. Mol Biol Cell (2007) 1.01
A thyrotoxic skeletal phenotype of advanced bone formation in mice with resistance to thyroid hormone. Mol Endocrinol (2003) 1.01
Suppression of the transformed phenotype of breast cancer by tropomyosin-1. Exp Cell Res (2002) 1.01
Cleavage of high-molecular-weight kininogen by elastase and tryptase is inhibited by ferritin. Am J Physiol Lung Cell Mol Physiol (2008) 1.01
Resistance to thyroid hormone is modulated in vivo by the nuclear receptor corepressor (NCOR1). Proc Natl Acad Sci U S A (2011) 1.00
Reactivation of the silenced thyroid hormone receptor β gene expression delays thyroid tumor progression. Endocrinology (2012) 1.00
SKI-606, an Src inhibitor, reduces tumor growth, invasion, and distant metastasis in a mouse model of thyroid cancer. Clin Cancer Res (2012) 0.99
Growth factor receptor expression varies among high-grade gliomas and normal brain: epidermal growth factor receptor has excellent properties for interstitial fusion protein therapy. Mol Cancer Ther (2003) 0.98
The pituitary tumor-transforming gene promotes angiogenesis in a mouse model of follicular thyroid cancer. Carcinogenesis (2006) 0.97
Adipogenesis is differentially impaired by thyroid hormone receptor mutant isoforms. J Mol Endocrinol (2010) 0.97
Inhibition of mTORC1 signaling reduces tumor growth but does not prevent cancer progression in a mouse model of thyroid cancer. Carcinogenesis (2010) 0.96
Thyroid hormone receptor beta mutants: Dominant negative regulators of peroxisome proliferator-activated receptor gamma action. Proc Natl Acad Sci U S A (2005) 0.96
Polymorphisms in drug metabolism genes, smoking, and p53 mutations in breast cancer. Mol Carcinog (2008) 0.96
Modulation by steroid receptor coactivator-1 of target-tissue responsiveness in resistance to thyroid hormone. Endocrinology (2003) 0.96
Thyroid hormones regulate fibroblast growth factor receptor signaling during chondrogenesis. Endocrinology (2005) 0.96
Nongenomic activation of phosphatidylinositol 3-kinase signaling by thyroid hormone receptors. Steroids (2008) 0.95
The Arf-inducing transcription factor Dmp1 encodes a transcriptional activator of amphiregulin, thrombospondin-1, JunB and Egr1. Int J Cancer (2010) 0.95
Oncolytic vesicular stomatitis virus induces apoptosis in U87 glioblastoma cells by a type II death receptor mechanism and induces cell death and tumor clearance in vivo. J Virol (2011) 0.95
Activation of antimetastatic Nm23-H1 gene expression by estrogen and its alpha-receptor. Endocrinology (2002) 0.94
Activation of caspase pathways during iron chelator-mediated apoptosis. J Biol Chem (2002) 0.94
Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers. Mod Pathol (2004) 0.93
Diet-induced obesity increases tumor growth and promotes anaplastic change in thyroid cancer in a mouse model. Endocrinology (2013) 0.92
Critical roles of DMP1 in human epidermal growth factor receptor 2/neu-Arf-p53 signaling and breast cancer development. Cancer Res (2010) 0.92
A tumor suppressor role for thyroid hormone beta receptor in a mouse model of thyroid carcinogenesis. Endocrinology (2004) 0.91
Chromosomal aberrations in cell lines derived from thyroid tumors spontaneously developed in TRbetaPV/PV mice. Cancer Genet Cytogenet (2005) 0.91
5-Oxo-ETE analogs and the proliferation of cancer cells. Biochim Biophys Acta (2005) 0.91
In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice. Cancer Res (2010) 0.91
Role of DMP1 and its future in lung cancer diagnostics. Expert Rev Mol Diagn (2008) 0.91
Dual functions of the steroid hormone receptor coactivator 3 in modulating resistance to thyroid hormone. Mol Cell Biol (2005) 0.91
Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials. Protein Expr Purif (2004) 0.90
Angiotensin-(1-7) attenuates metastatic prostate cancer and reduces osteoclastogenesis. Prostate (2012) 0.89
Thyroid hormone receptors regulate adipogenesis and carcinogenesis via crosstalk signaling with peroxisome proliferator-activated receptors. J Mol Endocrinol (2009) 0.87
Cardiac expression and function of thyroid hormone receptor beta and its PV mutant. Endocrinology (2003) 0.86
Functional activation of cerebral metabolism in mice with mutated thyroid hormone nuclear receptors. Endocrinology (2003) 0.86
The spectrum of resistance in SR/CR mice: the critical role of chemoattraction in the cancer/leukocyte interaction. BMC Cancer (2010) 0.85
The effect of aging on cellular immunity against cancer in SR/CR mice. Cancer Immunol Immunother (2004) 0.84
Perillyl alcohol-mediated inhibition of lung cancer cell line proliferation: potential mechanisms for its chemotherapeutic effects. Toxicol Appl Pharmacol (2004) 0.83
Inhibition of estrogen-dependent tumorigenesis by the thyroid hormone receptor β in xenograft models. Am J Cancer Res (2013) 0.82
Novel translocation responses of cytosolic phospholipase A2alpha fluorescent proteins. Biochim Biophys Acta (2008) 0.82
Nuclear receptor corepressor (NCOR1) regulates in vivo actions of a mutated thyroid hormone receptor α. Proc Natl Acad Sci U S A (2013) 0.82
Loss of heterozygosity and SOSTDC1 in adult and pediatric renal tumors. J Exp Clin Cancer Res (2010) 0.82
Compensatory role of thyroid hormone receptor (TR) alpha 1 in resistance to thyroid hormone: study in mice with a targeted mutation in the TR beta gene and deficient in TR alpha 1. Mol Endocrinol (2003) 0.82
Diphtheria toxin-epidermal growth factor fusion protein and Pseudomonas exotoxin-interleukin 13 fusion protein exert synergistic toxicity against human glioblastoma multiforme cells. Bioconjug Chem (2003) 0.82
Inhibition of tumorigenesis by the thyroid hormone receptor β in xenograft models. Thyroid (2013) 0.82
Cardiac glucose utilization in mice with mutated alpha- and beta-thyroid hormone receptors. Am J Physiol Endocrinol Metab (2004) 0.82
A histone deacetylase inhibitor improves hypothyroidism caused by a TRα1 mutant. Hum Mol Genet (2013) 0.81